

antipsychotic medications, except clozapine. **LIMITATIONS:** This is a non-randomized study.

P-18-16

Atypical antipsychotics and risk of first-time idiopathic venous thromboembolism: A case report

L. Borrás, A. Eytan, E. Constant, P. Huguelet. *University Hospital of Geneva Dept. of Psychiatry, Bruxelles-Belgique, Belgium*

Objective: Several studies and reports have demonstrated an increased risk of venous thromboembolism in patients treated with conventional antipsychotic drugs. Recent reports also indicate an association between clozapine and venous thromboembolic events; however, to our knowledge, thromboembolic complications have not yet been described in patients taking olanzapine or risperidone.

Methods: We report the case of a 28 year old man, suffering from a schizoaffective disorder, with no identified risk factors for thromboembolism, who developed such a complication on three occurrences, once during treatment with olanzapine and twice with risperidone.

Results: According to the literature, risk of venous thromboembolism is the highest during the three first months of treatment with atypical antipsychotics. The biological mechanisms responsible for this possible adverse drug reaction are unknown, but a number of hypotheses have been proposed. The increased risk may be the result of drug-induced sedation, obesity, hyperleptinemia,

antiphospholipid antibodies and increased activity in the coagulation system. The association could also be related to underlying risk factors present in patients with psychosis such as smoking, catatonia or physical restraint.

Conclusion: The case we report suggests that clinicians should be aware of this possible serious adverse drug reaction. Studies are needed in order to further elucidate this phenomenon, particularly to determine the incidence rate, possible predisposing factors and the biological mechanisms involved. This is particularly important since atypical antipsychotic drugs are now commonly prescribed, replacing conventional neuroleptics.

Tuesday, April 5, 2005

LS-05. Satellite symposium: The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning

**Luncheon Satellite
Supported by an unrestricted educational grant
from AstraZeneca**

12.30 - 14.00, Gasteig - Carl-Orff Hall
